Recombinant protein production in a human cell

Details Recombinant protein production in a human cell Recombinant protein production in a human cell

2006-11-07

2006-11-07

Chen, Stacy B. (Department: 1648)

Chemistry: molecular biology and microbiology

Animal cell, per se ; composition thereof; process of...

Animal cell, per se, expressing immunoglobulin, antibody, or...

C435S069100, C435S070210, C435S325000, C424S233100, C424S130100

Reexamination Certificate

active

07132280

ABSTRACT:
Methods and compositions for the production of recombinant proteins in a human cell line. The methods and compositions are particularly useful for generating stable expression of human recombinant proteins of interest that are modified post-translationally, for example, by glycosylation. Such proteins may have advantageous properties in comparison with their counterparts produced in non-human systems such as Chinese hamster ovary cells.

REFERENCES:
patent: 4703008 (1987-10-01), Lin
patent: 4835260 (1989-05-01), Shoemaker
patent: 5047335 (1991-09-01), Paulson et al.
patent: 5192539 (1993-03-01), Van Der Marel et al.
patent: 5441868 (1995-08-01), Lin
patent: 5457089 (1995-10-01), Fibi et al.
patent: 5494790 (1996-02-01), Sasaki et al.
patent: 5631158 (1997-05-01), Dorai et al.
patent: 5767078 (1998-06-01), Johnson et al.
patent: 5773569 (1998-06-01), Wrighton et al.
patent: 5789247 (1998-08-01), Ballay et al.
patent: 5830851 (1998-11-01), Wrighton et al.
patent: 5835382 (1998-11-01), Wilson et al.
patent: 5856298 (1999-01-01), Strickland
patent: 5994128 (1999-11-01), Fallaux et al.
patent: 6033908 (2000-03-01), Bout et al.
patent: 6037453 (2000-03-01), Jardieu et al.
patent: 6475753 (2002-11-01), Ruben et al.
patent: 6492169 (2002-12-01), Vogels et al.
patent: 6558948 (2003-05-01), Kochanek et al.
patent: 6653101 (2003-11-01), Cockett et al.
patent: 6855544 (2005-02-01), Hateboer et al.
patent: 6878549 (2005-04-01), Vogels et al.
patent: 2002/0116723 (2002-08-01), Grigliatti et al.
patent: 2003/0087437 (2003-05-01), Asada et al.
patent: 2003/0092160 (2003-05-01), Bout et al.
patent: 0 185 573 (1986-06-01), None
patent: 0 411 678 (1991-02-01), None
patent: 0 833 934 (1998-04-01), None
patent: WO 93/03163 (1993-02-01), None
patent: WO 95/05465 (1995-02-01), None
patent: WO 95/29994 (1995-11-01), None
patent: WO 97/00326 (1997-01-01), None
patent: WO 98/18926 (1998-05-01), None
patent: WO 98/39411 (1998-09-01), None
patent: WO 98/44141 (1998-10-01), None
patent: WO 99/05268 (1999-02-01), None
patent: WO 99/24068 (1999-05-01), None
patent: WO 00/61164 (2000-10-01), None
patent: WO 00/63403 (2000-10-01), None
patent: WO 01/38362 (2001-05-01), None
patent: WO 02/053580 (2002-07-01), None
patent: WO 03/038100 (2003-05-01), None
patent: WO 03/048197 (2003-06-01), None
patent: WO 03/048348 (2003-06-01), None
patent: WO 03/051927 (2003-06-01), None
patent: WO 2004/003176 (2004-01-01), None
patent: WO 2004/099396 (2004-11-01), None
PCT International Search Report, PCT/NL00/00247, dated Oct. 9, 2000, 3 pages.
Ghosh-Choudhury et al., Protein IX, a minor component of the human adenovirus capsid, is essential for the packaging of the full length genomes, The EMBO Journal, 1987, pp. 1733-39, vol. 6, No. 6.
Louis et al., Cloning and Sequencing of the Cellular—Viral Junctions from the Human Adenovirus Type 5 Transformed 293 Cell Line, Virology, 1997, pp. 423-29, vol. 233.
NCBI Entrez Nucleotide accession No. U38242.
NCBI Entrez Nucleotide accession No. NC—002018.
NCBI Entrez Nucleotide accession No. X02996 J01967 J01968 J01970 J01971 J01972 J01974 J01976 J01977 J01978 J01979 K00515 V00025 V00026 V00027 V0029.
Setoguchi et al., “Stimulation of Erythropoiesis by in vivo gene therapy: Physiologic consequences of transfer of the humanerythropoietin gene to experimental animals using an adenovirus vector,” Blood, Nov. 1,1994, pp. 2946-53, vol. 84, No. 9.
European Search Report 05 10 0732, Apr. 7, 2005.
Fallaux et al, “New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses,” Human Gene Therapy, Sep. 1, 1998, vol. 9, No. 1, pp. 1909-1917. Abstract.
Grand et al., “Modulation of the level of expression of cellular genes in adenovirus 12-infected and transformed human cells,” Eur Mol Biol Organ J. 1986, 5 (6) 1253-1260. Abstract.
Grand et al., “The high levels of p53 present in adenovirus early region 1-transformed human cells do not cause up-regulation of MDM2 expression,” Virology, 1995, vol. 210, No. 2, pp. 323-334. Abstract.
Yu et al., “Enhanced c-erbB-2
eu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A,” Cancer Res., 1993, 53 (4) 891-8. Abstract.
Bout et al., “Production of RCA-free batches of E1-deleted recombinant adenoviral vectors on PER C6, ” Nucleic Acids Symp. Ser. 1998, XP-002115716, pp. 35-36.
Bout et al., A novel packaging cell line (PER.C6) for efficient production of RCA-free batches of E1-deleted recombinant adenoviral vectors, Cancer Gene Therapy, 1997, pp. S32-S33, vol. 4, No. 6.
Bout et al., “Improved helper cells for RCA-free production of E1-deleted recombinant adenovirus vectors,” Cancer Gene Therapy, 1996, pp. S24, vol. 3, No.6.
Pau et al., Abstract, The human cell line PER.C6 provides a new manufacturing system for the production of influenza vaccines, Vaccine, Mar. 21, 2001, pp. 2716-21, vol. 19, No. 17-19.
Carroll et al., Abstract, Differential Infection of Receptor-modified Host Cells by Receptor-Specific Influenza Viruses, Virus Research, Sep. 1985, pp. 165-79, vol. 3, No. 2.
Schiedner et al., Abstract, Efficient transformation of primary human amniocytes by E1 functions of Ad5: generation of new cell lines for adenoviral vector production, 2000, Hum. Gene Ther. 11, 2105-2116.
Pazur et al., Abstract, Oligosaccharides as immunodeterminants of erythropoietin for two sets of anti-carbohydrate antibodies, Journal of Protein Chemistry, Nov. 2000, pp. 631-35, vol. 19, No. 8.
Cronan, Abstract, Biotination of Proteins in-vivo a post-translational modification to label purify and study proteins, Journal of Biological Chemistry, Jun. 25, 1990, pp. 10327-33, vol. 265, No. 18.
Stockwell et al., High-throughput screening of small molecules in Miniaturized Mammalian Cell-based Assays involving Post-translational Modifications, Chemistry and Biology, Feb. 1999, pp. 71-83, vol. 6, No. 2.
Pacitti et al., Inhibition of Reovirus Type 3 Binding to Host Cells by Sialylated Glycoproteins Is Mediated through the Viral Attachment Protein, Journal of Virology, May 1987, pp. 1407-15, vol. 61, No. 5, American Society for Microbiology.
Zhang et al., Stable expression of human alpha-2,6-sialytransferase in Chinese hamster ovary cells: functional consequences for human erythropoietin expression and bioactivity, BBA—General Subjects, 1998, pp. 441-52, vol. 1425, No. 3, Elsevier Science Publishers, NL.
Grabenhorst et al., Construction of stable BHK-21 cells coexpressing human secretory glycoproteins and human Gal(beta-1-4)GlcNAc-R alpha-2,6-sialytransferase alpha-2,6-Linked NeuAc is preferentially attached to the Gal(beta-1-4)GlcNAc(beta-1-2)Man(alpha-1-3)-branch of diantennary oligosaccharides from secreted recombinant beta-trace protein, Eur. J. Biochem, 1995, pp. 718-25, vol. 232, No. 3, Berlin, Germany.
Hollister et al., Stable expression of mammalian beta1,4-galactosyltransferase extends the N-glycosylation pathway in insect cells, Glycobiology, 1998, pp. 473-80, vol. 8, No. 5, IRL Press, United Kingdom.
Jenkins et al., Getting the glycosylation right: Implications for the biotechnology industry, Nature Biotechnology, Aug. 1996, pp. 975-81, vol. 14, No. 8, Nature Publishing, US.
Weikert et al., Engineering Chinese hamster ovary cells to maximize sialic acid content of recombinant glycoproteins, Nature Biotechnology, Nov. 1999, pp. 1116-21, vol. 17, No. 11, Nature Pub. Co., New York, NY, US.
Minch et al., Tissue Plasminogen Activator Coexpressed in Chinese Hamster Ovary Cells with alpha(2,6)-Sialytransferase Contains NeuAc-alpha(2,6)Gal-beta(1,4)Glc-N-AcR Linkages, Biotechnol. Prog., 1995, pp. 348-51, vol. 11, No. 3.
Opposition against European patent 1108787 filed Oct. 5, 2005 in the name and on behalf of Probiogen AG.
Graham et al., “Characteristics of a Human Cell Line Transformed by DNA from Human Adenovirus Tyoe 5,” J. Gen. Virol., 1977, pp. 59-72, vol. 36.
Graham, Cell Lines, Promochem (visited Apr. 10, 2005) <http://www.lgepro

Affiliated with

Also associated with

Rating

Recombinant protein production in a human cell does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Recombinant protein production in a human cell, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant protein production in a human cell will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3670364